Pharma & Healthcare
Global Antiangiogenic Drugs Market Research Report 2026
- Feb 24, 26
- ID: 720935
- Pages: 124
- Figures: 121
- Views: 1
This report delivers a comprehensive overview of the global Antiangiogenic Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antiangiogenic Drugs. The Antiangiogenic Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Antiangiogenic Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Antiangiogenic Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Bayer
Sanofi
Eli Lilly
Roche
Pfizer
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Novartis
AstraZeneca
Exelixis
Boehringer Ingelheim
Eisai
Janssen Biotech
Simcere
Segment by Type
Macromolecular Single-target Angiogenesis Inhibitor
Small Molecule Multi-target Angiogenesis Inhibitor
Endogenous Pan-target Angiogenesis Inhibitor
by Application
Cancer Therapy
Ophthalmic Diseases
Inflammatory and Autoimmune Diseases
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Antiangiogenic Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Antiangiogenic Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Antiangiogenic Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Antiangiogenic Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Bayer
Sanofi
Eli Lilly
Roche
Pfizer
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Novartis
AstraZeneca
Exelixis
Boehringer Ingelheim
Eisai
Janssen Biotech
Simcere
Segment by Type
Macromolecular Single-target Angiogenesis Inhibitor
Small Molecule Multi-target Angiogenesis Inhibitor
Endogenous Pan-target Angiogenesis Inhibitor
by Application
Cancer Therapy
Ophthalmic Diseases
Inflammatory and Autoimmune Diseases
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Antiangiogenic Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Antiangiogenic Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Antiangiogenic Drugs Market Overview
1.1 Product Definition
1.2 Antiangiogenic Drugs by Type
1.2.1 Global Antiangiogenic Drugs Market Value by Type: 2025 vs 2032
1.2.2 Macromolecular Single-target Angiogenesis Inhibitor
1.2.3 Small Molecule Multi-target Angiogenesis Inhibitor
1.2.4 Endogenous Pan-target Angiogenesis Inhibitor
1.3 Antiangiogenic Drugs by Application
1.3.1 Global Antiangiogenic Drugs Market Value by Application: 2025 vs 2032
1.3.2 Cancer Therapy
1.3.3 Ophthalmic Diseases
1.3.4 Inflammatory and Autoimmune Diseases
1.3.5 Other
1.4 Global Antiangiogenic Drugs Market Size Estimates and Forecasts
1.4.1 Global Antiangiogenic Drugs Revenue 2021–2032
1.4.2 Global Antiangiogenic Drugs Sales 2021–2032
1.4.3 Global Antiangiogenic Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Antiangiogenic Drugs Market Competition by Manufacturers
2.1 Global Antiangiogenic Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Antiangiogenic Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Antiangiogenic Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Antiangiogenic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Antiangiogenic Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Antiangiogenic Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Antiangiogenic Drugs, Date of Entry into the Industry
2.8 Global Antiangiogenic Drugs Market Competitive Situation and Trends
2.8.1 Global Antiangiogenic Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Antiangiogenic Drugs Players Market Share by Revenue
2.8.3 Global Antiangiogenic Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antiangiogenic Drugs Market Scenario by Region
3.1 Global Antiangiogenic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Antiangiogenic Drugs Sales by Region: 2021–2032
3.2.1 Global Antiangiogenic Drugs Sales by Region: 2021–2026
3.2.2 Global Antiangiogenic Drugs Sales by Region: 2027–2032
3.3 Global Antiangiogenic Drugs Revenue by Region: 2021–2032
3.3.1 Global Antiangiogenic Drugs Revenue by Region: 2021–2026
3.3.2 Global Antiangiogenic Drugs Revenue by Region: 2027–2032
3.4 North America Antiangiogenic Drugs Market Facts & Figures by Country
3.4.1 North America Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Antiangiogenic Drugs Sales by Country (2021–2032)
3.4.3 North America Antiangiogenic Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiangiogenic Drugs Market Facts & Figures by Country
3.5.1 Europe Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Antiangiogenic Drugs Sales by Country (2021–2032)
3.5.3 Europe Antiangiogenic Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiangiogenic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Antiangiogenic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Antiangiogenic Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Antiangiogenic Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antiangiogenic Drugs Market Facts & Figures by Country
3.7.1 Latin America Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Antiangiogenic Drugs Sales by Country (2021–2032)
3.7.3 Latin America Antiangiogenic Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antiangiogenic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Antiangiogenic Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Antiangiogenic Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antiangiogenic Drugs Sales by Type (2021–2032)
4.1.1 Global Antiangiogenic Drugs Sales by Type (2021–2026)
4.1.2 Global Antiangiogenic Drugs Sales by Type (2027–2032)
4.1.3 Global Antiangiogenic Drugs Sales Market Share by Type (2021–2032)
4.2 Global Antiangiogenic Drugs Revenue by Type (2021–2032)
4.2.1 Global Antiangiogenic Drugs Revenue by Type (2021–2026)
4.2.2 Global Antiangiogenic Drugs Revenue by Type (2027–2032)
4.2.3 Global Antiangiogenic Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Antiangiogenic Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Antiangiogenic Drugs Sales by Application (2021–2032)
5.1.1 Global Antiangiogenic Drugs Sales by Application (2021–2026)
5.1.2 Global Antiangiogenic Drugs Sales by Application (2027–2032)
5.1.3 Global Antiangiogenic Drugs Sales Market Share by Application (2021–2032)
5.2 Global Antiangiogenic Drugs Revenue by Application (2021–2032)
5.2.1 Global Antiangiogenic Drugs Revenue by Application (2021–2026)
5.2.2 Global Antiangiogenic Drugs Revenue by Application (2027–2032)
5.2.3 Global Antiangiogenic Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Antiangiogenic Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bayer Antiangiogenic Drugs Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sanofi Antiangiogenic Drugs Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Company Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Eli Lilly Antiangiogenic Drugs Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Roche
6.4.1 Roche Company Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Roche Antiangiogenic Drugs Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Pfizer Antiangiogenic Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Jiangsu Hengrui Pharmaceuticals
6.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.6.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.6.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio
6.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.7 Chia Tai Tianqing
6.7.1 Chia Tai Tianqing Company Information
6.7.2 Chia Tai Tianqing Description and Business Overview
6.7.3 Chia Tai Tianqing Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio
6.7.5 Chia Tai Tianqing Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Company Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Novartis Antiangiogenic Drugs Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Company Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 AstraZeneca Antiangiogenic Drugs Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Exelixis
6.10.1 Exelixis Company Information
6.10.2 Exelixis Description and Business Overview
6.10.3 Exelixis Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Exelixis Antiangiogenic Drugs Product Portfolio
6.10.5 Exelixis Recent Developments/Updates
6.11 Boehringer Ingelheim
6.11.1 Boehringer Ingelheim Company Information
6.11.2 Boehringer Ingelheim Description and Business Overview
6.11.3 Boehringer Ingelheim Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio
6.11.5 Boehringer Ingelheim Recent Developments/Updates
6.12 Eisai
6.12.1 Eisai Company Information
6.12.2 Eisai Description and Business Overview
6.12.3 Eisai Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Eisai Antiangiogenic Drugs Product Portfolio
6.12.5 Eisai Recent Developments/Updates
6.13 Janssen Biotech
6.13.1 Janssen Biotech Company Information
6.13.2 Janssen Biotech Description and Business Overview
6.13.3 Janssen Biotech Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Janssen Biotech Antiangiogenic Drugs Product Portfolio
6.13.5 Janssen Biotech Recent Developments/Updates
6.14 Simcere
6.14.1 Simcere Company Information
6.14.2 Simcere Description and Business Overview
6.14.3 Simcere Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Simcere Antiangiogenic Drugs Product Portfolio
6.14.5 Simcere Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antiangiogenic Drugs Industry Chain Analysis
7.2 Antiangiogenic Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiangiogenic Drugs Production Mode & Process Analysis
7.4 Antiangiogenic Drugs Sales and Marketing
7.4.1 Antiangiogenic Drugs Sales Channels
7.4.2 Antiangiogenic Drugs Distributors
7.5 Antiangiogenic Drugs Customer Analysis
8 Antiangiogenic Drugs Market Dynamics
8.1 Antiangiogenic Drugs Industry Trends
8.2 Antiangiogenic Drugs Market Drivers
8.3 Antiangiogenic Drugs Market Challenges
8.4 Antiangiogenic Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Antiangiogenic Drugs by Type
1.2.1 Global Antiangiogenic Drugs Market Value by Type: 2025 vs 2032
1.2.2 Macromolecular Single-target Angiogenesis Inhibitor
1.2.3 Small Molecule Multi-target Angiogenesis Inhibitor
1.2.4 Endogenous Pan-target Angiogenesis Inhibitor
1.3 Antiangiogenic Drugs by Application
1.3.1 Global Antiangiogenic Drugs Market Value by Application: 2025 vs 2032
1.3.2 Cancer Therapy
1.3.3 Ophthalmic Diseases
1.3.4 Inflammatory and Autoimmune Diseases
1.3.5 Other
1.4 Global Antiangiogenic Drugs Market Size Estimates and Forecasts
1.4.1 Global Antiangiogenic Drugs Revenue 2021–2032
1.4.2 Global Antiangiogenic Drugs Sales 2021–2032
1.4.3 Global Antiangiogenic Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Antiangiogenic Drugs Market Competition by Manufacturers
2.1 Global Antiangiogenic Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Antiangiogenic Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Antiangiogenic Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Antiangiogenic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Antiangiogenic Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Antiangiogenic Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Antiangiogenic Drugs, Date of Entry into the Industry
2.8 Global Antiangiogenic Drugs Market Competitive Situation and Trends
2.8.1 Global Antiangiogenic Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Antiangiogenic Drugs Players Market Share by Revenue
2.8.3 Global Antiangiogenic Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antiangiogenic Drugs Market Scenario by Region
3.1 Global Antiangiogenic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Antiangiogenic Drugs Sales by Region: 2021–2032
3.2.1 Global Antiangiogenic Drugs Sales by Region: 2021–2026
3.2.2 Global Antiangiogenic Drugs Sales by Region: 2027–2032
3.3 Global Antiangiogenic Drugs Revenue by Region: 2021–2032
3.3.1 Global Antiangiogenic Drugs Revenue by Region: 2021–2026
3.3.2 Global Antiangiogenic Drugs Revenue by Region: 2027–2032
3.4 North America Antiangiogenic Drugs Market Facts & Figures by Country
3.4.1 North America Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Antiangiogenic Drugs Sales by Country (2021–2032)
3.4.3 North America Antiangiogenic Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiangiogenic Drugs Market Facts & Figures by Country
3.5.1 Europe Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Antiangiogenic Drugs Sales by Country (2021–2032)
3.5.3 Europe Antiangiogenic Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiangiogenic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Antiangiogenic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Antiangiogenic Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Antiangiogenic Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antiangiogenic Drugs Market Facts & Figures by Country
3.7.1 Latin America Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Antiangiogenic Drugs Sales by Country (2021–2032)
3.7.3 Latin America Antiangiogenic Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antiangiogenic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiangiogenic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Antiangiogenic Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Antiangiogenic Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antiangiogenic Drugs Sales by Type (2021–2032)
4.1.1 Global Antiangiogenic Drugs Sales by Type (2021–2026)
4.1.2 Global Antiangiogenic Drugs Sales by Type (2027–2032)
4.1.3 Global Antiangiogenic Drugs Sales Market Share by Type (2021–2032)
4.2 Global Antiangiogenic Drugs Revenue by Type (2021–2032)
4.2.1 Global Antiangiogenic Drugs Revenue by Type (2021–2026)
4.2.2 Global Antiangiogenic Drugs Revenue by Type (2027–2032)
4.2.3 Global Antiangiogenic Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Antiangiogenic Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Antiangiogenic Drugs Sales by Application (2021–2032)
5.1.1 Global Antiangiogenic Drugs Sales by Application (2021–2026)
5.1.2 Global Antiangiogenic Drugs Sales by Application (2027–2032)
5.1.3 Global Antiangiogenic Drugs Sales Market Share by Application (2021–2032)
5.2 Global Antiangiogenic Drugs Revenue by Application (2021–2032)
5.2.1 Global Antiangiogenic Drugs Revenue by Application (2021–2026)
5.2.2 Global Antiangiogenic Drugs Revenue by Application (2027–2032)
5.2.3 Global Antiangiogenic Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Antiangiogenic Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bayer Antiangiogenic Drugs Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sanofi Antiangiogenic Drugs Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Company Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Eli Lilly Antiangiogenic Drugs Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Roche
6.4.1 Roche Company Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Roche Antiangiogenic Drugs Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Pfizer Antiangiogenic Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Jiangsu Hengrui Pharmaceuticals
6.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.6.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.6.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio
6.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.7 Chia Tai Tianqing
6.7.1 Chia Tai Tianqing Company Information
6.7.2 Chia Tai Tianqing Description and Business Overview
6.7.3 Chia Tai Tianqing Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio
6.7.5 Chia Tai Tianqing Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Company Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Novartis Antiangiogenic Drugs Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Company Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 AstraZeneca Antiangiogenic Drugs Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Exelixis
6.10.1 Exelixis Company Information
6.10.2 Exelixis Description and Business Overview
6.10.3 Exelixis Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Exelixis Antiangiogenic Drugs Product Portfolio
6.10.5 Exelixis Recent Developments/Updates
6.11 Boehringer Ingelheim
6.11.1 Boehringer Ingelheim Company Information
6.11.2 Boehringer Ingelheim Description and Business Overview
6.11.3 Boehringer Ingelheim Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio
6.11.5 Boehringer Ingelheim Recent Developments/Updates
6.12 Eisai
6.12.1 Eisai Company Information
6.12.2 Eisai Description and Business Overview
6.12.3 Eisai Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Eisai Antiangiogenic Drugs Product Portfolio
6.12.5 Eisai Recent Developments/Updates
6.13 Janssen Biotech
6.13.1 Janssen Biotech Company Information
6.13.2 Janssen Biotech Description and Business Overview
6.13.3 Janssen Biotech Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Janssen Biotech Antiangiogenic Drugs Product Portfolio
6.13.5 Janssen Biotech Recent Developments/Updates
6.14 Simcere
6.14.1 Simcere Company Information
6.14.2 Simcere Description and Business Overview
6.14.3 Simcere Antiangiogenic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Simcere Antiangiogenic Drugs Product Portfolio
6.14.5 Simcere Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antiangiogenic Drugs Industry Chain Analysis
7.2 Antiangiogenic Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiangiogenic Drugs Production Mode & Process Analysis
7.4 Antiangiogenic Drugs Sales and Marketing
7.4.1 Antiangiogenic Drugs Sales Channels
7.4.2 Antiangiogenic Drugs Distributors
7.5 Antiangiogenic Drugs Customer Analysis
8 Antiangiogenic Drugs Market Dynamics
8.1 Antiangiogenic Drugs Industry Trends
8.2 Antiangiogenic Drugs Market Drivers
8.3 Antiangiogenic Drugs Market Challenges
8.4 Antiangiogenic Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Antiangiogenic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antiangiogenic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antiangiogenic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antiangiogenic Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antiangiogenic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antiangiogenic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antiangiogenic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antiangiogenic Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antiangiogenic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antiangiogenic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antiangiogenic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Antiangiogenic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antiangiogenic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antiangiogenic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antiangiogenic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antiangiogenic Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Antiangiogenic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Antiangiogenic Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Antiangiogenic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Antiangiogenic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antiangiogenic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Antiangiogenic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antiangiogenic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antiangiogenic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antiangiogenic Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antiangiogenic Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antiangiogenic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antiangiogenic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antiangiogenic Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Antiangiogenic Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Antiangiogenic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Antiangiogenic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Antiangiogenic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antiangiogenic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antiangiogenic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Antiangiogenic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antiangiogenic Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Antiangiogenic Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Antiangiogenic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Antiangiogenic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Antiangiogenic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antiangiogenic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antiangiogenic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Antiangiogenic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer Antiangiogenic Drugs Product
Table 74. Bayer Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Sanofi Antiangiogenic Drugs Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Eli Lilly Company Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Eli Lilly Antiangiogenic Drugs Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Roche Company Information
Table 86. Roche Description and Business Overview
Table 87. Roche Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Roche Antiangiogenic Drugs Product
Table 89. Roche Recent Developments/Updates
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Pfizer Antiangiogenic Drugs Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Jiangsu Hengrui Pharmaceuticals Company Information
Table 96. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 97. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product
Table 99. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 100. Chia Tai Tianqing Company Information
Table 101. Chia Tai Tianqing Description and Business Overview
Table 102. Chia Tai Tianqing Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Chia Tai Tianqing Antiangiogenic Drugs Product
Table 104. Chia Tai Tianqing Recent Developments/Updates
Table 105. Novartis Company Information
Table 106. Novartis Description and Business Overview
Table 107. Novartis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Novartis Antiangiogenic Drugs Product
Table 109. Novartis Recent Developments/Updates
Table 110. AstraZeneca Company Information
Table 111. AstraZeneca Description and Business Overview
Table 112. AstraZeneca Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. AstraZeneca Antiangiogenic Drugs Product
Table 114. AstraZeneca Recent Developments/Updates
Table 115. Exelixis Company Information
Table 116. Exelixis Description and Business Overview
Table 117. Exelixis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Exelixis Antiangiogenic Drugs Product
Table 119. Exelixis Recent Developments/Updates
Table 120. Boehringer Ingelheim Company Information
Table 121. Boehringer Ingelheim Description and Business Overview
Table 122. Boehringer Ingelheim Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Boehringer Ingelheim Antiangiogenic Drugs Product
Table 124. Boehringer Ingelheim Recent Developments/Updates
Table 125. Eisai Company Information
Table 126. Eisai Description and Business Overview
Table 127. Eisai Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Eisai Antiangiogenic Drugs Product
Table 129. Eisai Recent Developments/Updates
Table 130. Janssen Biotech Company Information
Table 131. Janssen Biotech Description and Business Overview
Table 132. Janssen Biotech Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Janssen Biotech Antiangiogenic Drugs Product
Table 134. Janssen Biotech Recent Developments/Updates
Table 135. Simcere Company Information
Table 136. Simcere Description and Business Overview
Table 137. Simcere Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Simcere Antiangiogenic Drugs Product
Table 139. Simcere Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Antiangiogenic Drugs Distributors List
Table 143. Antiangiogenic Drugs Customers List
Table 144. Antiangiogenic Drugs Market Trends
Table 145. Antiangiogenic Drugs Market Drivers
Table 146. Antiangiogenic Drugs Market Challenges
Table 147. Antiangiogenic Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antiangiogenic Drugs
Figure 2. Global Antiangiogenic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antiangiogenic Drugs Market Share by Type: 2025 & 2032
Figure 4. Macromolecular Single-target Angiogenesis Inhibitor Product Picture
Figure 5. Small Molecule Multi-target Angiogenesis Inhibitor Product Picture
Figure 6. Endogenous Pan-target Angiogenesis Inhibitor Product Picture
Figure 7. Global Antiangiogenic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Antiangiogenic Drugs Market Share by Application: 2025 & 2032
Figure 9. Cancer Therapy
Figure 10. Ophthalmic Diseases
Figure 11. Inflammatory and Autoimmune Diseases
Figure 12. Other
Figure 13. Global Antiangiogenic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Antiangiogenic Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Antiangiogenic Drugs Sales (K Units), 2021–2032
Figure 16. Global Antiangiogenic Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Antiangiogenic Drugs Report Years Considered
Figure 18. Antiangiogenic Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Antiangiogenic Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Antiangiogenic Drugs Players: Market Share by Revenue in Antiangiogenic Drugs in 2025
Figure 21. Antiangiogenic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Antiangiogenic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Antiangiogenic Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Antiangiogenic Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Antiangiogenic Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Antiangiogenic Drugs by Type (2021–2032)
Figure 56. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Antiangiogenic Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Antiangiogenic Drugs by Application (2021–2032)
Figure 59. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Antiangiogenic Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Antiangiogenic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antiangiogenic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antiangiogenic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antiangiogenic Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antiangiogenic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antiangiogenic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antiangiogenic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antiangiogenic Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antiangiogenic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antiangiogenic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antiangiogenic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Antiangiogenic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antiangiogenic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antiangiogenic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antiangiogenic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antiangiogenic Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Antiangiogenic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Antiangiogenic Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Antiangiogenic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Antiangiogenic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antiangiogenic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Antiangiogenic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antiangiogenic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antiangiogenic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antiangiogenic Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antiangiogenic Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antiangiogenic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antiangiogenic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antiangiogenic Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Antiangiogenic Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Antiangiogenic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Antiangiogenic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Antiangiogenic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antiangiogenic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antiangiogenic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Antiangiogenic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antiangiogenic Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Antiangiogenic Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Antiangiogenic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Antiangiogenic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Antiangiogenic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antiangiogenic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antiangiogenic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Antiangiogenic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer Antiangiogenic Drugs Product
Table 74. Bayer Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Sanofi Antiangiogenic Drugs Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Eli Lilly Company Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Eli Lilly Antiangiogenic Drugs Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Roche Company Information
Table 86. Roche Description and Business Overview
Table 87. Roche Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Roche Antiangiogenic Drugs Product
Table 89. Roche Recent Developments/Updates
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Pfizer Antiangiogenic Drugs Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Jiangsu Hengrui Pharmaceuticals Company Information
Table 96. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 97. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product
Table 99. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 100. Chia Tai Tianqing Company Information
Table 101. Chia Tai Tianqing Description and Business Overview
Table 102. Chia Tai Tianqing Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Chia Tai Tianqing Antiangiogenic Drugs Product
Table 104. Chia Tai Tianqing Recent Developments/Updates
Table 105. Novartis Company Information
Table 106. Novartis Description and Business Overview
Table 107. Novartis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Novartis Antiangiogenic Drugs Product
Table 109. Novartis Recent Developments/Updates
Table 110. AstraZeneca Company Information
Table 111. AstraZeneca Description and Business Overview
Table 112. AstraZeneca Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. AstraZeneca Antiangiogenic Drugs Product
Table 114. AstraZeneca Recent Developments/Updates
Table 115. Exelixis Company Information
Table 116. Exelixis Description and Business Overview
Table 117. Exelixis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Exelixis Antiangiogenic Drugs Product
Table 119. Exelixis Recent Developments/Updates
Table 120. Boehringer Ingelheim Company Information
Table 121. Boehringer Ingelheim Description and Business Overview
Table 122. Boehringer Ingelheim Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Boehringer Ingelheim Antiangiogenic Drugs Product
Table 124. Boehringer Ingelheim Recent Developments/Updates
Table 125. Eisai Company Information
Table 126. Eisai Description and Business Overview
Table 127. Eisai Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Eisai Antiangiogenic Drugs Product
Table 129. Eisai Recent Developments/Updates
Table 130. Janssen Biotech Company Information
Table 131. Janssen Biotech Description and Business Overview
Table 132. Janssen Biotech Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Janssen Biotech Antiangiogenic Drugs Product
Table 134. Janssen Biotech Recent Developments/Updates
Table 135. Simcere Company Information
Table 136. Simcere Description and Business Overview
Table 137. Simcere Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Simcere Antiangiogenic Drugs Product
Table 139. Simcere Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Antiangiogenic Drugs Distributors List
Table 143. Antiangiogenic Drugs Customers List
Table 144. Antiangiogenic Drugs Market Trends
Table 145. Antiangiogenic Drugs Market Drivers
Table 146. Antiangiogenic Drugs Market Challenges
Table 147. Antiangiogenic Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antiangiogenic Drugs
Figure 2. Global Antiangiogenic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antiangiogenic Drugs Market Share by Type: 2025 & 2032
Figure 4. Macromolecular Single-target Angiogenesis Inhibitor Product Picture
Figure 5. Small Molecule Multi-target Angiogenesis Inhibitor Product Picture
Figure 6. Endogenous Pan-target Angiogenesis Inhibitor Product Picture
Figure 7. Global Antiangiogenic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Antiangiogenic Drugs Market Share by Application: 2025 & 2032
Figure 9. Cancer Therapy
Figure 10. Ophthalmic Diseases
Figure 11. Inflammatory and Autoimmune Diseases
Figure 12. Other
Figure 13. Global Antiangiogenic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Antiangiogenic Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Antiangiogenic Drugs Sales (K Units), 2021–2032
Figure 16. Global Antiangiogenic Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Antiangiogenic Drugs Report Years Considered
Figure 18. Antiangiogenic Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Antiangiogenic Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Antiangiogenic Drugs Players: Market Share by Revenue in Antiangiogenic Drugs in 2025
Figure 21. Antiangiogenic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Antiangiogenic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Antiangiogenic Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Antiangiogenic Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Antiangiogenic Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Antiangiogenic Drugs by Type (2021–2032)
Figure 56. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Antiangiogenic Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Antiangiogenic Drugs by Application (2021–2032)
Figure 59. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Antiangiogenic Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232